UCLA Scientists Engineer Low-Cost T-Cell Therapy Targeting Solid Tumors

In laboratories at UCLA, scientists have quietly crossed a threshold that oncologists have long hoped for: T cells engineered to fight solid tumors — the cancers that claim the vast majority of lives — through two simultaneous mechanisms, and at a cost that places treatment within reach of far more of humanity. Where previous immunotherapies transformed blood cancer care but left solid tumor patients largely behind, this dual-function approach attacks the defenses tumors have evolved to hide behind. The science is promising, the economics are striking, and the question now is whether the long